ArticleInternational journal of molecular sciences2026
Molecular Proliferation Marker Ki-67 in Breast Cancer: The Role of Vitamin D Status, Hormone Receptor Expression, and Clinicopathological Factors-A Cross-Sectional Study.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ki-67 is a well-established nuclear biomarker of tumor cell proliferation with key importance for the molecular classification and prognostic stratification of breast cancer. This cross-sectional study included 101 women with histopathologically confirmed invasive breast cancer treated at the St. John of Dukla Oncology Center of the Lublin Region (COZL), Poland (2018-2019). Ki-67 expression was assessed immunohistochemically on formalin-fixed, paraffin-embedded tumor tissue, and independent predictors were identified using multiple linear regression. The median Ki-67 was 20% (IQR: 15-40%). Ki-67 differed significantly between molecular subtypes (Kruskal-Wallis test H = 16.122;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.